Indivior Pharmaceuticals, Inc.
boothcheck covers Indivior Pharmaceuticals, Inc. (INDV) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 27, 2026.
• Indivior is a specialty pharma focused on opioid-use-disorder treatment, and its story has narrowed to one drug: SUBLOCADE, a monthly buprenorphine injection that generated $856 million in 2025 and is growing fast [Source: Indivior FY2025 results, 8-K]. • The capital-allocation pivot is the theme: management is running the Indivior Action Agenda, discontinuing PERSERIS and OPVEE marketing and optimizing the international business for at least $150 million of annual cost savings in 2026 [Source
Is INDV overvalued? See what's priced in →
278 institutional managers reported holding INDV in 13F filings for the quarter ended 2026-03-31. Together they hold about 93% of the company; the top 10 hold 51%. 76 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 11.9M shares were sold short as of the 2026-06-15 count, about 9% of shares outstanding (7.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at INDV over the trailing three years: 2026: 3 buys totaling $31k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
INDV's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2025-08-01 | +20.9% | +10.1% |
| 2025-10-31 | +16.3% | +21.7% |
| 2026-02-27 | -2.7% | +15.0% |
| 2026-05-01 | +10.1% | pending |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
INDV's latest 8-K filings: 2026-08-03 (items 7.01, 9.01); 2026-08-03 (items 2.02, 7.01, 9.01); 2026-08-03 (items 1.01, 7.01, 9.01); 2026-05-15 (items 5.02, 5.07); 2026-05-04 (items 7.01, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.